Article Details

Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401)

Retrieved on: 2021-07-30 09:33:45

Tags for this article:

Click the tags to see associated articles and topics

Late-Breaking AAIC Presentation Explores Potential Clinical Effects Of Lecanemab (BAN2401). View article details on HISWAI: https://pipelinereview.com/index.php/2021073078862/Antibodies/Late-Breaking-AAIC-Presentation-Explores-Potential-Clinical-Effects-Of-Lecanemab-BAN2401.html

Excerpt

Lecanemab is an investigational humanized monoclonal antibody that preferentially binds to soluble amyloid-beta (Aβ) aggregates (protofibrils).

Article found on: pipelinereview.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up